Dietrich John Pauls - 01 Jun 2025 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role: President & CEO, Director
Signature: /s/ Scott Kellen, attorney-in-fact
Issuer symbol: DMAC
Transactions as of: 01 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 03 Jun 2025, 16:18:01 UTC
Previous filing: 03 Jun 2024
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Pauls Dietrich John	President & CEO, Director	301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS	/s/ Scott Kellen, attorney-in-fact	03 Jun 2025	0001760123

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	DMAC	Voting Common Shares, no par value per share						68,591	01 Jun 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DMAC	Stock Option (right to buy)	Award	$0	+600,000		$0.000000	600,000	01 Jun 2025	Common Shares	600,000	$4.11	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.
F2	Vests with respect to 25% of the underlying common shares on June 1, 2026 with the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2026.